Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: Results of a single-center study

Bone Marrow Transplantation

Volumn 27, Issue 1, 2001, Pages 27-33

  Blau, I W ^a   Basara, N ^a   Lentini, G ^a   Guenzelmann, S ^a   Kirsten, D ^a   Schmetzer, B ^a   Bischoff, M ^a   Roemer, E ^a   Kiehl, M G ^a   Fauser, A A ^a  

^a Clinic for Bone Marrow Transplantation and Hematology/Oncology   (Germany)

Author keywords

BMT; GVHD; HLA compatibility; PBSCT

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; BUSULFAN; CD3 ANTIGEN; CD34 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; ITRACONAZOLE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THIOTEPA;

ACUTE DISEASE; ADULT; ARTICLE; BLOOD DISEASE; BLOOD DONOR; BLOOD SAMPLING; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CELL COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; CONDITIONING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RELATIVE; SAFETY; THROMBOCYTE; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BLOOD DONORS; BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; INFECTION; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 17744380426     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702734     Document Type: Article

References (31)

1. Allogeneic transplantation of blood-derived. T cell-depleted hematopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia
2. Transplantation of allogeneic peripheral blood progenitor cells - The EBMT experience
3. Allogeneic blood stem cell transplantation: Peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thyldim) and lymphoid subsets, and possible predictors of engraftment and disease
4. Allogeneic blood cell transplants for haematological malignancy: Preliminary comparison of outcomes with bone marrow transplantation
5. Allogeneic peripheral blood progenitor cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation
6. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow
7. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemia burden, donor HLA-matching, and marrow cell dose
8. Allogeneic peripheral blood progenitor cell transplantation: Analysis of short-term engraftment and acute GVHD incidence in 33 cases
9. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
10. A trend towards an increased incidences of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: A case controlled study
11. A prospective, randomized trail of peripheral blood stem cell (PBSC) transplants or marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies
12. A randomized trial of filgrastim (G-CSF) stimulated donor marrow (BM) versus peripheral blood (PBSC) for allogeneic transplantation: Increased extensive chronic GVHD following PBSC transplantation
13. Blood stem cell procurement: Donor safety issues
14. The effects of daily recombinant human granulocyte colony stimulating factor administration on normal granulocyte donors undergoing leukapheresis
15. Spontaneous splenic rupture following administration of granulocyte colony stimulating factor (G-CSF): Occurence in an allogeneic donor of peripheral blood stem cells
16. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients
17. Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival using peripheral blood stem cells from related and unrelated donors, compared to bone marrow
18. Bone marrow transplantation
19. Meeting report: Concensus conference on acute GVHD grading
20. Chronic graft-versus-host syndrome in man. A long term clinicopathologic study of 20 Seattle patients
21. Design and analysis of randomized clinical trails requiring prolonged observation of each patient. II. Analysis and examples
22. Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease
23. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Societe Française de Greffe de Moelle
24. Allogeneic bone marrow transplantation vs filgrastim-mobilized peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomized multicenter trial of the European group for Marrow Transplantation
25. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation
26. + cells from an HLA-identical unrelated donor
27. Pretreatment of donor mice with granulocyte colony stimulating factor polarizes donor T-lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host-disease
28. Comparison of HLA-identical allogeneic bone marrow (BM) versus peripheral blood stem cells (PBSC) transplantation: Phenotypical and functional study of donor T cells in the graft and after hematopoietic reconstitution
29. Allogeneic blood stem cell transplantation: Considerations for donors
30. And NK cell counts in healthy donors at 1 year after blood stem cell harvesting